Introduction of pneumococcal vaccine in national immunisation schedule in India: boon or bane?
Abstract
Vaccination is undoubtedly one of the most cost-effective child survival public health measure which are more affordable and accessible to community in preventing diseases. Government of India has undertaken several initiatives to strengthen maternal and child health services in the country and child immunisation being an important part of child healthcare system in India. The National Immunization Programme has taken many initiatives since its inception as Expanded Programme on Immunization in 1978. In recent years, there has been introduction of various newer vaccines. Introduction of pneumococcal vaccine in selected states in year 2017 and plan to scale up in the entire country is the newest change in National Immunization Schedule. This review aims to identify various articles related to pneumococcal infection and vaccine highlighting the burden, serotypic distribution, available vaccines, evidence regarding vaccine safety, efficacy, acceptability and cost effectiveness, in order to provide sufficient understanding on the demand and need of this vaccine in India. Important factors underpinned by this article are though there is a need of vaccination due to severe form of pneumococcal infections and antibiotic resistance due to which many developed countries have included PCV in their regular immunisation programmes, however studies regarding effectiveness of pneumococcal vaccines in developing countries like India, data regarding the burden of pneumococcal infections are not available. Also there are limited studies investigating the bacterial and viral etiology of Community Acquired Pneumonia and lack of data to show change in the serotype prevalence overtime. This review highlights the need of more research to provide substantial clinical and epidemiological evidence for the introduction of pneumococcal vaccine.
Downloads
References
Govt. Of India. Ministry of Health and Family Welfare. National Vaccine Policy. New Delhi; 2011 Apr.23p. Available fromhttps://mohfw.gov.in/
Govt. Of India. Ministry of Health and Family Welfare. National Family Health survey (NFHS-4), India Facts sheet. Available from: http://rchiips.org/nfhs/factsheet.shtml last accessed on 18.11.2018
Lahariya C. A brief history of vaccines & vaccination in India. Indian J Med Res. 2014 Apr 139(4) :491-511
Government of India and UNICEF, Ministry of Health and Family Welfare. Coverage evaluation survey: all India report 2009.Available from: www.unicef.org/india
WHO and Maternal and Child Epidemiology Estimation Group (MCEE). Estimates of child cause of death, Acute respiratory infection 2015. Available from http://apps.who.int/gho/data/node.main.
Yadav KK, Awasthi S. The current status of community acquired pneumonia management and prevention in children under 5 years of age in India: a review. Ther Adv Inf Dis. 2016 Jun; 3(3-4) :83–97. doi: 10.1177/2049936116652326.
Black RE, Cousens S, Johnson HL et al. Global, regional, and national causes of child mortality in 2008: a systemic analysis.The Lancet.2010 Jun 5;375(9730):1969-87. doi: 10.1016/S0140-6736(10)60549-1.
WHO. Pneumonia. Key facts. [Internet]. [Updated 2019 Aug 2; cited 2019 Nov 18].Available from: http://www.who.int/mediacentre/factsheets/fs331/en/
WHO. Immunization, Vaccines and Biologicals. Pneumococcal disease [Internet]. 2014
[Updated: 2014 Sep 29; cited 2019 Nov 18].Available from: http://www.who.int/immunization/topics/pneumococcal_disease/en/
Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008; 86(5): 408–416. doi : 10.2471/blt.07.048769
Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000. Lancet 2012 Jun 9; 379: 2151–2161. doi: 10.1016/S0140-6736(12)60560-1.
Jaiswal N, Singh M, Thumburu KK, Bharti B, Agarwal A, Kumar A et al. Burden of Invasive Pneumococcal Disease in Children Aged 1 Month to 12 Years Living in South Asia: A Systematic Review. PLOS ONE. 2014 May5;9 (5 ): e96282. doi : https://doi.org/10.1371/journal.pone.0096282
Johnson HL, Deloria K M, Levine OS et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: The pneumococcal global serotype project . PLoS Med 2010; 7 (10): e 1000348. doi : https : // doi . org / 10. 1371 / journal. pmed.1000348
Thomas K. Invasive Bacterial Infections Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN). Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Lancet 1999 Apr 10; 353(9160): 1216–1221. doi: https://doi.org/10.1016/S0140-6736(98)07228-6
Manoharan A. Surveillance of invasive disease caused by Streptococcus pneumoniae or Hemophilus influenzae or Neisseria meningitides in children (<5 Years) in India. Alliance for Surveillance of Pneumococci (ASIP). Poster Discussion 2: Bacterial Infections 1, 13:30 to 15:30 Hours, May 30, 2013 at the 31st Annual Meeting of the European Society for Paediatric Infectious Diseases; May 28eJune 1, 2013. Milan, Italy
Malik A, Taneja DK. Conjugate Pneumococcal Vaccines: Need and Choice in India. Indian J Community Med. 2013 Oct-Dec; 38(4): 189–191.doi: 10.4103/0970-0218.120140
Amdekar YK, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India. Pediatr Infect Dis J. 2013;32(5):509-16. doi: 10.1097/INF.0b013e31827b478d
Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, et al. Effectiveness of the ten‑valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD‑CV10) against invasive pneumococcal disease: A cluster randomised trial. Lancet 2013;381(9862):214‑22.doi: 10.1016/S0140-6736(12)61854-6.
Van de Vooren K, Duranti S, Curto A, Garattini L. Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics. 2014 Jan;32(1):29-45. doi: 10.1007/s40273-013-0113-y
Y. Madhavi, Puliyel J M, Mathew J L, N. Raghuram, Phadke A, Shiva M, S. Srinivasan et al. Evidence-based National Vaccine Policy Indian J Med Res, 2010 May; 131: 617-628.
Zodpey S, Farooqui H, Chokshi M, B R, Thacker N. Pediatricians' perspectives on pneumococcal conjugate vaccines: An exploratory study in the private sector.Ind Journal of public Health, 2015;59 (3): 225-229. doi: 10.4103/0019-557X.164667
Kahn GD, Thacker D, Nimbalkar S, Santosham M. High cost is the primary barrier reported by physicians who prescribe vaccines not included in India's Universal Immunization Program. J Trop Pediatr. 2014 Aug;60(4):287-91. doi: 10.1093
Predictors of administration and attitudes about pneumococcal, Haemophilus influenzae type b and rotavirus vaccines among pediatricians in India: A national survey. J Vaccine. 2012 May 21;30(24):3541-5. doi: 10.1016
Farooqui H H, Zodpey S, Chokshi M, Thacker N. Estimates on State-Specific Pneumococcal Conjugate Vaccines (PCV) Coverage in the Private Sector in the Year 2012: Evidence from PCV Utilizatio Data. Indian J Public Health. 2016 Apr-Jun;60(2):145-9. doi: 10.4103/0019-557X.184572.
Kanungo R. Challenges to pneumococcal vaccine in India. Indian J Med Microbiol 2013;31:1-2.doi: 10.4103/0255-0857.108701
Copyright (c) 2019 Author (s). Published by Siddharth Health Research and Social Welfare Society
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI - Open Archives Initiative
